|
1
|
Klöppel G: Neuroendocrine neoplasms:
Dichotomy, origin and classifications. Visc Med. 33:324–330.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gheorghișan-Gălățeanu AA, Ilieșiu A,
Lambrescu IM and Țăpoi DA: The complex histopathological and
immunohistochemical spectrum of neuroendocrine tumors-an overview
of the latest classifications. Int J Mol Sci.
24(1418)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
The International Agency for Research on
Cancer (IARC): Global Cancer Observatory. https://gco.iarc.who.int/. Accessed October 2,
2025.
|
|
4
|
Durma AD, Saracyn M, Kołodziej M,
Jóźwik-Plebanek K, Dmochowska B, Kapusta W, Żmudzki W, Mróz A,
Kos-Kudła B and Kamiński G: Epidemiology of neuroendocrine
neoplasms and results of their treatment with
[177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE
and [90Y]Y-DOTA-TATE-A six-year experience in
high-reference polish neuroendocrine neoplasm center. Cancers
(Basel). 15(5466)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Guccione L, Gough K, Drosdowsky A, Price
T, Pavlakis N, Wyld D, Ransom D, Michael M and Schofield P: The
unmet information needs, quality of life, and care experiences of
patients with neuroendocrine tumours (NETs) at follow-up: 6 months
from diagnosis. Support Care Cancer. 31(577)2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Helderman NC, Suerink M, Kilinç G, van den
Berg JG, Nielsen M and Tesselaar MET: Relation between WHO
classification and location- and functionality-based
classifications of neuroendocrine neoplasms of the digestive tract.
Neuroendocrinology. 114:120–133. 2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Park JH, Shin SJ, Jeon N and Lim BJ:
Clinicopathologic characteristics of neuroendocrine tumors with
assessment by digital image analysis for Ki-67 index with a focus
on the gastroenteropancreatic tract: A single-center study. Int J
Clin Exp Pathol. 16:225–234. 2023.PubMed/NCBI
|
|
8
|
Zandee WT, Kamp K, van Adrichem RC,
Feelders RA and de Herder WW: Effect of hormone secretory syndromes
on neuroendocrine tumor prognosis. Endocr Relat Cancer.
24:R261–R274. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hofland J and de Herder WW:
Gastrointestinal neuroendocrine tumors and the carcinoid syndrome.
(Updated 2023 Aug 25). In: Endotext [Internet]. Feingold KR, Adler
RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de
Herder WW, Dhatariya K, Dungan K, et al (eds). MDText.com, Inc., South Dartmouth, MA, 2000.
|
|
10
|
Chan CS, Laddha SV, Lewis PW, Koletsky MS,
Robzyk K, Da Silva E, Torres PJ, Untch BR, Li J, Bose P, et al:
ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a
distinct alpha-cell signature subgroup. Nat Commun.
9(4158)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Coman M, Hîncu M, Surlin P, Mateescu G,
Nechita A and Banu M: Comparative histomorphometric study of bone
tissue synthesized after electric and ultrasound stimulation. Rom J
Morphol Embryol. 52 (Suppl 1):S455–S458. 2011.PubMed/NCBI
|
|
12
|
Thakker RV: Multiple endocrine neoplasia
type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 386:2–15.
2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Feng Z, Wang L, Sun Y, Jiang Z, Domsic J,
An C, Xing B, Tian J, Liu X, Metz DC, et al: Menin and Daxx
interact to suppress neuroendocrine tumors through epigenetic
control of the membrane metallo-endopeptidase. Cancer Res.
77:401–411. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Metz DC and Jensen RT: Gastrointestinal
neuroendocrine tumors: Pancreatic endocrine tumors.
Gastroenterology. 135:1469–1492. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sulciner ML and Clancy TE: Surgical
maknagement of pancreatic neuroendocrine tumors. Cancers (Basel).
15(2006)2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lee DW, Kim MK and Kim HG: Diagnosis of
pancreatic neuroendocrine tumors. Clin Endosc. 50:537–545.
2017.
|
|
17
|
Neuroendocrine Tumor Research Foundation:
A new treatment option for NET patients. Retrieved from https://netrf.org/2025/03/26/a-new-treatment-option-for-net-patients/.
Accessed March 27, 2025.
|
|
18
|
Alkaissi H, Talvacchio S, Derkyi A, Gubbi
S, Pappo A, Gordon CM, Glod J, Zhuang Z and Pacak K: Belzutifan for
HIF2A-related pheochromocytoma and paraganglioma: A retrospective
study of real-world data. Endocr Pract. 32:201–205. 2026.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Prado-Wohlwend S, Bernal-Vergara JC,
Utrera-Costero A, Cañón-Sánchez JR, Agudelo-Cifuentes M and
Bello-Arques P: Endocrinology Working Group of the SEMNIM. Peptide
receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE.
Rev Esp Med Nucl Imagen Mol (Engl Ed). 41:55–65. 2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Reddy RP, Ross Schmidtlein C, Giancipoli
RG, Mauguen A, LaFontaine D, Schoder H and Bodei L: The quest for
an accurate functional tumor volume with 68Ga-DOTATATE
PET/CT. J Nucl Med. 63:1027–1032. 2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Reubi JC and Schonbrunn A: Illuminating
somatostatin analog action at neuroendocrine tumor receptors.
Trends Pharmacol Sci. 34:676–688. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Soliman NA and Yussif SM: Ki-67 as a
prognostic marker according to breast cancer molecular subtype.
Cancer Biol Med. 13:496–504. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Souche R, Hobeika C, Hain E and Gaujoux S:
Surgical management of neuroendocrine tumours of the pancreas. J
Clin Med. 9(2993)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
O'Neill CB, Atoria CL, O'Reilly EM, Henman
MC, Bach PB, Elkin EB, O'Neill CB, Atoria CL, O'Reilly EM, Henman
MC, et al: ReCAP: Hospitalizations in older adults with advanced
cancer: The role of chemotherapy. J Oncol Pract. 12:151–152,
e138-e148. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Siddiqui Z, Marginean H, Leung M, Asmis T,
Vickers M and Goodwin R: Real world use of lanreotide in
neuroendocrine tumors. J Gastrointest Oncol. 14:1488–1495.
2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Phan AT and Dave B: The pivotal role of
mammalian target of rapamycin inhibition in the treatment of
patients with neuroendocrine tumors. Cancer Med. 5:2953–2964.
2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Delbaldo C, Faivre S, Dreyer C and Raymond
E: Sunitinib in advanced pancreatic neuroendocrine tumors: Latest
evidence and clinical potential. Ther Adv Med Oncol. 4:9–18.
2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Deacu S, Neculai-Cândea L, Pricop S,
Aschie M, Mocanu L and Popa M: Vascular adhesive peptide-1 (VAP-1)
expression in wounds-a new vital reaction marker? Rom J Leg Med.
29:347–351. 2021.
|
|
29
|
Bundschuh RA, Habacha B, Lütje S and
Essler M: Therapy of patients with neuroendocrine
neoplasia-evidence-based approaches and new horizons. J Clin Med.
8(1474)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Pan WX, Zhang XM, Hao SL and Han W:
Progress in immunotherapy for neuroendocrine neoplasm of the
digestive system. World J Gastroenterol. 29:4174–4185.
2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. Syst Rev. 10(89)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Covvey JR, McClendon C and Gionfriddo MR:
Back to the basics: Guidance for formulating good research
questions. Res Social Adm Pharm. 20:66–69. 2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Icahn School of Medicine at Mount Sinai:
Evidence based medicine: The PICO framework. https://libguides.mssm.edu/ebm/ebp_pico. Accessed
July 2, 2024.
|
|
34
|
MIT Libraries: Database search tips:
Boolean operators. https://libguides.mit.edu/c.php?g=175963&p=1158594.
Accessed July 2, 2024.
|
|
35
|
Cochrane Methods Bias: RoB 2: A revised
Cochrane risk-of-bias tool for randomized trials. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials.
Aaccessed July 12, 2024.
|
|
36
|
Marušić MF, Fidahić M, Cepeha CM, Farcaș
LG, Tseke A and Puljak L: Methodological tools and sensitivity
analysis for assessing quality or risk of bias used in systematic
reviews published in the high-impact anesthesiology journals. BMC
Med Res Methodol. 20(121)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kabir R, Syed HZ, Hayhoe R, Parsa AD,
Sivasubramanian M, Mohammadnezhad M, Sathian B, Kizhessery R, Jain
M, Gandhi PA, et al: Meta-analysis using SPSS: A simple guide for
clinicians, public health, and allied health specialists. Evidence.
2:1–24. 2024.
|
|
38
|
Kwak S: Are only P-values less than 0.05
significant? A P-value greater than 0.05 is also significant! J
Lipid Atheroscler. 12:89–95. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Page MJ, Moher D, Bossuyt PM, Boutron I,
Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: PRISMA 2020 explanation and elaboration: updated
guidance and exemplars for reporting systematic reviews. BMJ.
372(n160)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Innocenti T, Feller D, Giagio S, Salvioli
S, Minnucci S, Brindisino F, Cosentino C, Piano L, Chiarotto A and
Ostelo R: Adherence to the PRISMA statement and its association
with risk of bias in systematic reviews published in rehabilitation
journals: A meta-research study. Braz J Phys Ther.
26(100450)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Patel SP, Othus M, Chae YK, Giles FJ,
Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, et
al: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1
blockade in rare tumors (DART SWOG 1609) in patients with
nonpancreatic neuroendocrine tumors. Clin Cancer Res. 26:2290–2296.
2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite instability/mismatch
repair-deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 38:1–10. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Tawbi HA, Schadendorf D, Lipson EJ,
Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas
HJ, Lao CD, De Menezes JJ, et al: Relatlimab and nivolumab versus
nivolumab in untreated advanced melanoma. N Engl J Med. 386:24–34.
2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Puca L, Gavyert K, Sailer V, Conteduca V,
Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L,
et al: Delta-like protein 3 expression and therapeutic targeting in
neuroendocrine prostate cancer. Sci Transl Med.
11(eaav0891)2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J,
Dummer R, et al: Five-year survival with combined nivolumab and
ipilimumab in advanced melanoma. N Engl J Med. 381:1535–1546.
2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Jonasch E, Donskov F, Iliopoulos O,
Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie
JK, Welsh SJ, et al: Belzutifan for renal cell carcinoma in von
hippel-lindau disease. N Engl J Med. 385:2036–2046. 2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Morizane C, Machida N, Honma Y, Okusaka T,
Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, et al:
Effectiveness of etoposide and cisplatin vs irinotecan and
cisplatin therapy for patients with advanced neuroendocrine
carcinoma of the digestive system: The TOPIC-NEC phase 3 randomized
clinical trial. JAMA Oncol. 8:1447–1455. 2022.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Amaria RN, Reddy SM, Tawbi HA, Davies MA,
Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, et al:
Neoadjuvant immune checkpoint blockade in high-risk resectable
melanoma. Nat Med. 24:1649–1654. 2018.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Motzer RJ, McDermott DF, Escudier B,
Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta
C, George S, et al: Conditional survival and long-term efficacy
with nivolumab plus ipilimumab versus sunitinib in patients with
advanced renal cell carcinoma. Cancer. 128:2085–2097.
2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ott PA, Hu-Lieskovan S, Chmielowski B,
Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD,
Lin JJ, et al: A phase Ib trial of personalized neoantigen therapy
plus anti-PD-1 in patients with advanced melanoma, non-small cell
lung cancer, or bladder cancer. Cell. 183:347–362.e24.
2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Dummer R, Hauschild A, Santinami M,
Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni V, Larkin J,
Nyakas M, Dutriaux C, et al: Five-year analysis of adjuvant
dabrafenib plus trametinib in stage III melanoma. N Engl J Med.
383:1139–1148. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Eggermont AMM, Blank CU, Mandala M, Long
GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A,
Carlino MS, et al: Adjuvant pembrolizumab versus placebo in
resected stage III melanoma. N Engl J Med. 378:1789–1801.
2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Taylor MH, Lee CH, Makker V, Rasco D,
Dutcus CE, Wu J, Stepan DE, Shumaker RC and Motzer RJ: Phase IB/II
trial of lenvatinib plus pembrolizumab in patients with advanced
renal cell carcinoma, endometrial cancer, and other selected
advanced solid tumors. J Clin Oncol. 38:1154–1163. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Olson DJ, Eroglu Z, Brockstein B,
Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J,
Higgs E, et al: Pembrolizumab plus ipilimumab following
anti-PD-1/L1 failure in melanoma. J Clin Oncol. 39:2647–2655.
2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Chauhan A, Farooqui Z, Murray LA, Weiss
HL, War Myint Z, Raajasekar AKA, Evers BM, Arnold S and Anthony L:
Capecitabine and temozolomide in neuroendocrine tumor of unknown
primary. J Oncol. 2018(3519247)2018.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Topalian SL, Bhatia S, Amin A, Kudchadkar
RR, Sharfman WH, Lebbé C, Delord JP, Dunn LA, Shinohara MM,
Kulikauskas R, et al: Neoadjuvant nivolumab for patients with
resectable merkel cell carcinoma in the CheckMate 358 trial. J Clin
Oncol. 38:2476–2487. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Pavel M, Lahner H, Hörsch D, Rinke A,
Denecke T, Koch A, Regnault B, Helbig D, Hoffmanns P and Raderer M:
Combined lanreotide autogel and temozolomide treatment of
progressive pancreatic and intestinal neuroendocrine tumors: The
phase II SONNET study. Oncologist. 29:e643–e654. 2024.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Leidner R, Conlon K, McNeel DG,
Wang-Gillam A, Gupta S, Wesolowski R, Chaudhari M, Hassounah N, Lee
JB, Ho Lee L, et al: First-in-human phase I/Ib study of NIZ985, a
recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and
in combination with spartalizumab in patients with advanced and
metastatic solid tumors. J Immunother Cancer.
11(e007725)2023.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Reidy-Lagunes D, Pandit-Taskar N,
O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N,
Gönen M, Lohrmann C, et al: Phase I trial of well-differentiated
neuroendocrine tumors (NETs) with radiolabeled somatostatin
antagonist 177Lu-satoreotide tetraxetan. Clin Cancer Res.
25:6939–6947. 2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Iyer RV, Konda B, Fountzilas C, Mukherjee
S, Owen D, Attwood K, Wang C, Maguire O, Minderman H, Suffren SA,
et al: Multicenter phase 2 trial of nintedanib in advanced
nonpancreatic neuroendocrine tumors. Cancer. 126:3689–3697.
2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Rinke A, Maintz C, Müller L, Weber MM,
Lahner H, Pavel M, Saeger W, Houchard A, Ungewiss H and Petersenn
S: Multicenter, observational study of lanreotide autogel for the
treatment of patients with neuroendocrine tumors in routine
clinical practice in Germany and Austria. Exp Clin Endocrinol
Diabetes. 129:500–509. 2021.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Singh S, Halperin D, Myrehaug S, Herrmann
K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J,
et al: [177Lu]Lu-DOTA-TATE plus long-acting octreotide
versus high-dose long-acting octreotide for the treatment of newly
diagnosed, advanced grade 2-3, well-differentiated,
gastroenteropancreatic neuroendocrine tumours (NETTER-2): An
open-label, randomised, phase 3 study. Lancet. 403:2807–2817.
2024.
|
|
63
|
Rich JT, Neely JG, Paniello RC, Voelker
CC, Nussenbaum B and Wang EW: A practical guide to understanding
Kaplan-Meier curves. Otolaryngol Head Neck Surg. 143:331–336.
2010.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Dudley WN, Wickham R and Coombs N: An
introduction to survival statistics: Kaplan-Meier analysis. J Adv
Pract Oncol. 7:91–100. 2016.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Goel MK, Khanna P and Kishore J:
Understanding survival analysis: Kaplan-Meier estimate. Int J
Ayurveda Res. 1:274–278. 2010.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Riffenburgh RH (ed): Chapter 25 - Survival
and time-series analysis. In: Statistics in Medicine. 2nd edition.
Academic Press, pp487-519, 2006.
|
|
67
|
Turkson AJ, Ayiah-Mensah F, Nimoh V and
Tang N: Handling censoring and censored data in survival analysis:
A standalone systematic literature review. Int J Math Math Sci.
2021:1–16. 2021.
|
|
68
|
Ro C, Chai W, Yu VE and Yu R: Pancreatic
neuroendocrine tumors: Biology, diagnosis, and treatment. Chin J
Cancer. 32:312–324. 2013.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Kurakawa KI, Okada A, Manaka K, Konishi T,
Jo T, Ono S, Uda K, Michihata N, Matsui H, Fushimi K, et al:
Clinical characteristics and incidences of benign and malignant
insulinoma using a national inpatient database in Japan. J Clin
Endocrinol Metab. 106:3477–3486. 2021.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Pánczél G, Horváth P, Temaj E, Czirbesz K,
Kispál MT, Fröhlich G and Balatoni T: Real-world outcomes of
ipilimumab-nivolumab vs Anti-PD-1 monotherapy in metastatic uveal
melanoma: A single-center retrospective study. Cancers (Basel).
17(3521)2025.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Hektoen HH, Tsuruda KM, Fjellbirkeland L,
Nilssen Y, Brustugun OT and Andreassen BK: Real-world evidence for
pembrolizumab in non-small cell lung cancer: A nationwide cohort
study. Br J Cancer. 132:93–102. 2025.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Choucair K, Odabashian R, Reddy SN, Azmi
AS and Saif MW: An update on novel pharmacotherapies for the
treatment of neuroendocrine tumors. Int J Mol Sci.
26(11095)2025.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Wild D, Grønbæk H, Navalkissoor S, Haug A,
Nicolas GP, Pais B, Ansquer C, Beauregard JM, McEwan A, Lassmann M,
et al: A phase I/II study of the safety and efficacy of
[177Lu]Lu-satoreotide tetraxetan in advanced
somatostatin receptor-positive neuroendocrine tumours. Eur J Nucl
Med Mol Imaging. 51:183–195. 2023.PubMed/NCBI View Article : Google Scholar
|
